{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:50:50Z","timestamp":1794084650538,"version":"4.8.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00428-025-04354-5","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T21:58:28Z","timestamp":1764107908000},"page":"473-488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The shifting paradigm of programmed cell death ligand 1 (PD-L1) in anaplastic thyroid carcinoma: from pathology to clinical practice"],"prefix":"10.1007","volume":"488","author":[{"given":"Vincenzo","family":"Fiorentino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagiovanna","family":"Ballato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Zuccal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pizzimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mondello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cannav\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Campenn\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Tralongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giuffr\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1349-0910","authenticated-orcid":false,"given":"Gabriele","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Fadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Diana","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"4354_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115173","volume":"26","author":"A Forma","year":"2025","unstructured":"Forma A, K\u0142odnicka K, Paj\u0105k W et al (2025) Thyroid cancer: epidemiology, classification, risk factors, diagnostic and prognostic markers, and current treatment strategies. Int J Mol Sci 26:5173. https:\/\/doi.org\/10.3390\/ijms26115173","journal-title":"Int J Mol Sci"},{"key":"4354_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12020-022-03146-0","volume":"78","author":"C Pizzimenti","year":"2022","unstructured":"Pizzimenti C, Fiorentino V, Ieni A et al (2022) Aggressive variants of follicular cell-derived thyroid carcinoma: an overview. Endocrine 78:1\u201312. https:\/\/doi.org\/10.1007\/s12020-022-03146-0","journal-title":"Endocrine"},{"key":"4354_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11061043","volume":"11","author":"V Fiorentino","year":"2021","unstructured":"Fiorentino V, Dell\u2019 Aquila M, Musarra T et al (2021) The role of cytology in the diagnosis of subcentimeter thyroid lesions. Diagnostics 11:1043. https:\/\/doi.org\/10.3390\/diagnostics11061043","journal-title":"Diagnostics"},{"key":"4354_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/PAP.0000000000000357","volume":"29","author":"ED Rossi","year":"2022","unstructured":"Rossi ED, Tralongo P, Fiorentino V et al (2022) Approach to FNA of thyroid gland cysts. Adv Anat Pathol 29:358\u2013364. https:\/\/doi.org\/10.1097\/PAP.0000000000000357","journal-title":"Adv Anat Pathol"},{"key":"4354_CR5","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","volume":"30","author":"S Filetti","year":"2019","unstructured":"Filetti S, Durante C, Hartl D et al (2019) Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 30:1856\u20131883. https:\/\/doi.org\/10.1093\/annonc\/mdz400","journal-title":"Ann Oncol"},{"key":"4354_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/674583","volume":"2014","author":"NM Lowe","year":"2014","unstructured":"Lowe NM, Loughran S, Slevin NJ, Yap BK (2014) Anaplastic thyroid cancer: the addition of systemic chemotherapy to radiotherapy led to an observed improvement in survival\u2014a single centre experience and review of the literature. Sci World J 2014:674583. https:\/\/doi.org\/10.1155\/2014\/674583","journal-title":"Sci World J"},{"key":"4354_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nrendo.2017.76","volume":"13","author":"E Molinaro","year":"2017","unstructured":"Molinaro E, Romei C, Biagini A et al (2017) Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol 13:644\u2013660. https:\/\/doi.org\/10.1038\/nrendo.2017.76","journal-title":"Nat Rev Endocrinol"},{"key":"4354_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125535","volume":"26","author":"S Schipor","year":"2025","unstructured":"Schipor S, Publik MA, Manda D, Ceausu M (2025) Aggressive thyroid carcinomas clinical and molecular features: a systematic review. Int J Mol Sci 26:5535. https:\/\/doi.org\/10.3390\/ijms26125535","journal-title":"Int J Mol Sci"},{"key":"4354_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101678","volume":"37","author":"SN Rao","year":"2023","unstructured":"Rao SN, Smallridge RC (2023) Anaplastic thyroid cancer: an update. Best Pract Res Clin Endocrinol Metab 37:101678. https:\/\/doi.org\/10.1016\/j.beem.2022.101678","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"4354_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/790834","volume":"2014","author":"M Ragazzi","year":"2014","unstructured":"Ragazzi M, Ciarrocchi A, Sancisi V et al (2014) Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol 2014:790834. https:\/\/doi.org\/10.1155\/2014\/790834","journal-title":"Int J Endocrinol"},{"key":"4354_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s13353-020-00594-0","volume":"62","author":"J Mika","year":"2021","unstructured":"Mika J, \u0141abaj W, Chekan M et al (2021) The mutation profile of differentiated thyroid cancer coexisting with undifferentiated anaplastic cancer resembles that of anaplastic thyroid cancer but not that of archetypal differentiated thyroid cancer. J Appl Genet 62:115\u2013120. https:\/\/doi.org\/10.1007\/s13353-020-00594-0","journal-title":"J Appl Genet"},{"key":"4354_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1677\/ERC-08-0154","volume":"16","author":"RC Smallridge","year":"2009","unstructured":"Smallridge RC, Marlow LA, Copland JA (2009) Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16:17\u201344. https:\/\/doi.org\/10.1677\/ERC-08-0154","journal-title":"Endocr Relat Cancer"},{"key":"4354_CR13","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/cncy.22454","volume":"129","author":"M Dell\u2019Aquila","year":"2021","unstructured":"Dell\u2019Aquila M, Fiorentino V, Martini M et al (2021) How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: role of TERT promoter and BRAF V600E mutation analysis. Cancer Cytopathol 129:819\u2013829. https:\/\/doi.org\/10.1002\/cncy.22454","journal-title":"Cancer Cytopathol"},{"key":"4354_CR14","doi-asserted-by":"publisher","first-page":"1178682","DOI":"10.3389\/fimmu.2023.1178682","volume":"14","author":"L Gui","year":"2023","unstructured":"Gui L, Zhu Y, Li X et al (2023) Case report: complete response of an anaplastic thyroid carcinoma patient with NRAS Q61R\/BRAF D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody. Front Immunol 14:1178682. https:\/\/doi.org\/10.3389\/fimmu.2023.1178682","journal-title":"Front Immunol"},{"key":"4354_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.18632\/oncotarget.28544","volume":"15","author":"M Lee","year":"2024","unstructured":"Lee M, Morris LG (2024) Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation. Oncotarget 15:36\u201348. https:\/\/doi.org\/10.18632\/oncotarget.28544","journal-title":"Oncotarget"},{"key":"4354_CR16","doi-asserted-by":"publisher","unstructured":"Pacini F, Castagna MG, Brilli L et al (2012) Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii110\u2013119. https:\/\/doi.org\/10.1093\/annonc\/mds230","DOI":"10.1093\/annonc\/mds230"},{"key":"4354_CR17","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"Maniakas A, Dadu R, Busaidy NL et al (2020) Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000\u20132019. JAMA Oncol 6:1397\u20131404. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3362","journal-title":"JAMA Oncol"},{"key":"4354_CR18","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.21037\/gs-2019-ursoc-08","volume":"10","author":"YJ Song","year":"2021","unstructured":"Song YJ (2021) Prediction of optimal debulking surgery in ovarian cancer. Gland Surg 10:1173\u20131181. https:\/\/doi.org\/10.21037\/gs-2019-ursoc-08","journal-title":"Gland Surg"},{"key":"4354_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010179","volume":"15","author":"J Yuan","year":"2022","unstructured":"Yuan J, Guo Y (2022) Targeted therapy for anaplastic thyroid carcinoma: advances and management. Cancers (Basel) 15:179. https:\/\/doi.org\/10.3390\/cancers15010179","journal-title":"Cancers (Basel)"},{"key":"4354_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.21873\/invivo.12279","volume":"35","author":"T Augustin","year":"2021","unstructured":"Augustin T, Oliinyk D, Rauch J et al (2021) Radiation to the primary tumor in metastatic anaplastic thyroid cancer. In Vivo 35:461\u2013465. https:\/\/doi.org\/10.21873\/invivo.12279","journal-title":"In Vivo"},{"key":"4354_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1469167","volume":"15","author":"T Liu","year":"2025","unstructured":"Liu T, Xu C, Chen H et al (2025) Ultrasound-guided radiofrequency ablation for the treatment of anaplastic thyroid cancer: a case report. Front Oncol 15:1469167. https:\/\/doi.org\/10.3389\/fonc.2025.1469167","journal-title":"Front Oncol"},{"key":"4354_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/cncy.22224","volume":"128","author":"M Dell\u2019Aquila","year":"2020","unstructured":"Dell\u2019Aquila M, Granitto A, Martini M et al (2020) PD-L1 and thyroid cytology: a possible diagnostic and prognostic marker. Cancer Cytopathol 128:177\u2013189. https:\/\/doi.org\/10.1002\/cncy.22224","journal-title":"Cancer Cytopathol"},{"key":"4354_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/jclinpath-2022-208215","volume":"76","author":"M Dell\u2019Aquila","year":"2023","unstructured":"Dell\u2019Aquila M, Tralongo P, Granitto A et al (2023) Update regarding the role of PD-L1 in oncocytic thyroid lesions on cytological samples. J Clin Pathol 76:671\u2013677. https:\/\/doi.org\/10.1136\/jclinpath-2022-208215","journal-title":"J Clin Pathol"},{"key":"4354_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677\u2013704. https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090331","journal-title":"Annu Rev Immunol"},{"key":"4354_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0770-2","volume":"7","author":"S Chen","year":"2019","unstructured":"Chen S, Crabill GA, Pritchard TS et al (2019) Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer 7:305. https:\/\/doi.org\/10.1186\/s40425-019-0770-2","journal-title":"J Immunother Cancer"},{"key":"4354_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126750","volume":"25","author":"E German\u00e0","year":"2024","unstructured":"German\u00e0 E, Pepe L, Pizzimenti C et al (2024) Programmed cell death ligand 1 (PD-L1) immunohistochemical expression in advanced urothelial bladder carcinoma: an updated review with clinical and pathological implications. Int J Mol Sci 25:6750. https:\/\/doi.org\/10.3390\/ijms25126750","journal-title":"Int J Mol Sci"},{"key":"4354_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010676","volume":"25","author":"V Fiorentino","year":"2024","unstructured":"Fiorentino V, Pizzimenti C, Franchina M et al (2024) Programmed cell death ligand 1 immunohistochemical expression and cutaneous melanoma: a controversial relationship. Int J Mol Sci 25:676. https:\/\/doi.org\/10.3390\/ijms25010676","journal-title":"Int J Mol Sci"},{"key":"4354_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE (2018) The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18:153\u2013167. https:\/\/doi.org\/10.1038\/nri.2017.108","journal-title":"Nat Rev Immunol"},{"key":"4354_CR29","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887\u20133895. https:\/\/doi.org\/10.1002\/j.1460-2075.1992.tb05481.x","journal-title":"EMBO J"},{"key":"4354_CR30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7\u2013H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793\u2013800. https:\/\/doi.org\/10.1038\/nm730","journal-title":"Nat Med"},{"key":"4354_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/jclinpath-2017-204853","volume":"71","author":"A Kythreotou","year":"2018","unstructured":"Kythreotou A, Siddique A, Mauri FA et al (2018) PD-L1. J Clin Pathol 71:189\u2013194. https:\/\/doi.org\/10.1136\/jclinpath-2017-204853","journal-title":"J Clin Pathol"},{"key":"4354_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315384","volume":"23","author":"PG Meliante","year":"2022","unstructured":"Meliante PG, Barbato C, Zoccali F et al (2022) Programmed cell death-ligand 1 in head and neck squamous cell carcinoma: molecular insights, preclinical and clinical data, and therapies. Int J Mol Sci 23:15384. https:\/\/doi.org\/10.3390\/ijms232315384","journal-title":"Int J Mol Sci"},{"key":"4354_CR33","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00262-018-2226-9","volume":"67","author":"Y Shi","year":"2018","unstructured":"Shi Y (2018) Regulatory mechanisms of PD-L1 expression in cancer cells. Cancer Immunol Immunother 67:1481\u20131489. https:\/\/doi.org\/10.1007\/s00262-018-2226-9","journal-title":"Cancer Immunol Immunother"},{"key":"4354_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13020363","volume":"13","author":"I Girolami","year":"2023","unstructured":"Girolami I, Marletta S, Fiorentino V et al (2023) Effect of radio-chemotherapy on PD-L1 immunohistochemical expression in head and neck squamous cell carcinoma. J Pers Med 13:363. https:\/\/doi.org\/10.3390\/jpm13020363","journal-title":"J Pers Med"},{"key":"4354_CR35","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.7150\/jca.57334","volume":"12","author":"C Ghosh","year":"2021","unstructured":"Ghosh C, Luong G, Sun Y (2021) A snapshot of the PD-1\/PD-L1 pathway. J Cancer 12:2735\u20132746. https:\/\/doi.org\/10.7150\/jca.57334","journal-title":"J Cancer"},{"key":"4354_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216318","volume":"569","author":"Q Lin","year":"2023","unstructured":"Lin Q, Wang X, Hu Y (2023) The opportunities and challenges in immunotherapy: insights from the regulation of PD-L1 in cancer cells. Cancer Lett 569:216318. https:\/\/doi.org\/10.1016\/j.canlet.2023.216318","journal-title":"Cancer Lett"},{"key":"4354_CR37","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/apm.13218","volume":"130","author":"E Pakkanen","year":"2022","unstructured":"Pakkanen E, Kalfert D, Ahtiainen M et al (2022) PD-L1 and PD-1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor. APMIS 130:276\u2013283. https:\/\/doi.org\/10.1111\/apm.13218","journal-title":"APMIS"},{"key":"4354_CR38","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41420-025-02688-2","volume":"11","author":"J Zhang","year":"2025","unstructured":"Zhang J, Zheng S, Xie R et al (2025) Epigenetic control in thyroid cancer: mechanisms and clinical perspective. Cell Death Discov 11:387. https:\/\/doi.org\/10.1038\/s41420-025-02688-2","journal-title":"Cell Death Discov"},{"key":"4354_CR39","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s12253-020-00834-y","volume":"26","author":"L Heged\u0171s","year":"2020","unstructured":"Heged\u0171s L, Rittler D, Garay T et al (2020) HDAC inhibition induces PD-L1 expression in a novel anaplastic thyroid cancer cell line. Pathol Oncol Res 26:2523\u20132535. https:\/\/doi.org\/10.1007\/s12253-020-00834-y","journal-title":"Pathol Oncol Res"},{"key":"4354_CR40","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1210\/jc.2012-3566","volume":"98","author":"S Rodr\u00edguez-Rodero","year":"2013","unstructured":"Rodr\u00edguez-Rodero S, Fern\u00e1ndez AF, Fern\u00e1ndez-Morera JL et al (2013) DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab 98:2811\u20132821. https:\/\/doi.org\/10.1210\/jc.2012-3566","journal-title":"J Clin Endocrinol Metab"},{"key":"4354_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.70207","author":"DC de Mello","year":"2025","unstructured":"de Mello DC, Cristov\u00e3o MM, Henrique G et al (2025) Targeting EZH2 reverses thyroid cell dedifferentiation and enhances iodide uptake in anaplastic thyroid cancer. FEBS Lett. https:\/\/doi.org\/10.1002\/1873-3468.70207","journal-title":"FEBS Lett"},{"key":"4354_CR42","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1210\/jc.2010-1784","volume":"96","author":"E Borbone","year":"2011","unstructured":"Borbone E, Troncone G, Ferraro A et al (2011) Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. J Clin Endocrinol Metab 96:1029\u20131038. https:\/\/doi.org\/10.1210\/jc.2010-1784","journal-title":"J Clin Endocrinol Metab"},{"key":"4354_CR43","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1038\/s41418-023-01217-x","volume":"30","author":"J Ning","year":"2023","unstructured":"Ning J, Hou X, Hao J et al (2023) METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer. Cell Death Differ 30:2265\u20132279. https:\/\/doi.org\/10.1038\/s41418-023-01217-x","journal-title":"Cell Death Differ"},{"key":"4354_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.568931","volume":"11","author":"K Hudson","year":"2020","unstructured":"Hudson K, Cross N, Jordan-Mahy N, Leyland R (2020) The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment. Front Immunol 11:568931. https:\/\/doi.org\/10.3389\/fimmu.2020.568931","journal-title":"Front Immunol"},{"key":"4354_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00386","volume":"8","author":"P Dong","year":"2018","unstructured":"Dong P, Xiong Y, Yue J et al (2018) Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. Front Oncol 8:386. https:\/\/doi.org\/10.3389\/fonc.2018.00386","journal-title":"Front Oncol"},{"key":"4354_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210024","volume":"24","author":"C Pizzimenti","year":"2023","unstructured":"Pizzimenti C, Fiorentino V, Ieni A et al (2023) BRAF-AXL-PD-L1 signaling axis as a possible biological marker for RAI treatment in the thyroid cancer ATA intermediate risk category. Int J Mol Sci 24:10024. https:\/\/doi.org\/10.3390\/ijms241210024","journal-title":"Int J Mol Sci"},{"key":"4354_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111436","volume":"138","author":"P Lotfinejad","year":"2021","unstructured":"Lotfinejad P, Kazemi T, Safaei S et al (2021) PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines. Biomed Pharmacother 138:111436. https:\/\/doi.org\/10.1016\/j.biopha.2021.111436","journal-title":"Biomed Pharmacother"},{"key":"4354_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3892\/or.2020.7831","volume":"45","author":"C-J Li","year":"2021","unstructured":"Li C-J, Lin L-T, Hou M-F, Chu P-Y (2021) PD-L1\/PD-1 blockade in breast cancer: the immunotherapy era (Review). Oncol Rep 45:5\u201312. https:\/\/doi.org\/10.3892\/or.2020.7831","journal-title":"Oncol Rep"},{"key":"4354_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020307","volume":"14","author":"M N\u00fa\u00f1ez Abad","year":"2022","unstructured":"N\u00fa\u00f1ez Abad M, Calabuig-Fari\u00f1as S, de Lobo Mena M et al (2022) Programmed death-ligand 1 (PD-L1) as immunotherapy biomarker in breast cancer. Cancers (Basel) 14:307. https:\/\/doi.org\/10.3390\/cancers14020307","journal-title":"Cancers (Basel)"},{"key":"4354_CR50","doi-asserted-by":"publisher","unstructured":"K K, N Z, E C et al (2019) Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of Pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med 143. https:\/\/doi.org\/10.5858\/arpa.2018-0043-OA","DOI":"10.5858\/arpa.2018-0043-OA"},{"key":"4354_CR51","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu Y-L, Kudaba I et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393:1819\u20131830. https:\/\/doi.org\/10.1016\/S0140-6736(18)32409-7","journal-title":"Lancet"},{"key":"4354_CR52","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394:1915\u20131928. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7","journal-title":"Lancet"},{"key":"4354_CR53","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393:156\u2013167. https:\/\/doi.org\/10.1016\/S0140-6736(18)31999-8","journal-title":"Lancet"},{"key":"4354_CR54","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1097\/PAS.0000000000002284","volume":"48","author":"S Agarwal","year":"2024","unstructured":"Agarwal S, Jung CK, Gaddam P et al (2024) PD-L1 expression and its modulating factors in anaplastic thyroid carcinoma: a multi-institutional study. Am J Surg Pathol 48:1233\u20131244. https:\/\/doi.org\/10.1097\/PAS.0000000000002284","journal-title":"Am J Surg Pathol"},{"key":"4354_CR55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12022-018-9514-y","volume":"29","author":"MW Rosenbaum","year":"2018","unstructured":"Rosenbaum MW, Gigliotti BJ, Pai SI et al (2018) PD-L1 and IDO1 are expressed in poorly differentiated thyroid carcinoma. Endocr Pathol 29:59\u201367. https:\/\/doi.org\/10.1007\/s12022-018-9514-y","journal-title":"Endocr Pathol"},{"key":"4354_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.712107","volume":"12","author":"P Adam","year":"2021","unstructured":"Adam P, Kircher S, Sbiera I et al (2021) FGF-receptors and PD-L1 in anaplastic and poorly differentiated thyroid cancer: evaluation of the preclinical rationale. Front Endocrinol (Lausanne) 12:712107. https:\/\/doi.org\/10.3389\/fendo.2021.712107","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4354_CR57","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/ERC-16-0421","volume":"24","author":"S Ahn","year":"2017","unstructured":"Ahn S, Kim TH, Kim SW et al (2017) Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer 24:97\u2013106. https:\/\/doi.org\/10.1530\/ERC-16-0421","journal-title":"Endocr Relat Cancer"},{"key":"4354_CR58","doi-asserted-by":"publisher","unstructured":"Kemal Y, Caliskan S, Gun S, Kefeli M. PD-L1 Expression in medullary thyroid carcinoma and its association with clinicopathological findings. Turk Patoloji Derg 38:106\u2013113. https:\/\/doi.org\/10.5146\/tjpath.2021.01558","DOI":"10.5146\/tjpath.2021.01558"},{"key":"4354_CR59","doi-asserted-by":"publisher","first-page":"e67004","DOI":"10.7759\/cureus.67004","volume":"16","author":"N Anand","year":"2024","unstructured":"Anand N, Srivastava P, Husain N et al (2024) Evaluation of CTLA-4 and PD-L1 expression in thyroid carcinoma and its prognostic significance. Cureus 16:e67004. https:\/\/doi.org\/10.7759\/cureus.67004","journal-title":"Cureus"},{"key":"4354_CR60","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s12253-014-9876-5","volume":"21","author":"H Wu","year":"2015","unstructured":"Wu H, Sun Y, Ye H et al (2015) Anaplastic thyroid cancer: outcome and the mutation\/expression profiles of potential targets. Pathol Oncol Res 21:695\u2013701. https:\/\/doi.org\/10.1007\/s12253-014-9876-5","journal-title":"Pathol Oncol Res"},{"key":"4354_CR61","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1210\/jc.2015-4227","volume":"101","author":"JJ Bastman","year":"2016","unstructured":"Bastman JJ, Serracino HS, Zhu Y et al (2016) Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 101:2863\u20132873. https:\/\/doi.org\/10.1210\/jc.2015-4227","journal-title":"J Clin Endocrinol Metab"},{"key":"4354_CR62","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/his.13230","volume":"71","author":"K Zwaenepoel","year":"2017","unstructured":"Zwaenepoel K, Jacobs J, De Meulenaere A et al (2017) CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy. Histopathology 71:357\u2013365. https:\/\/doi.org\/10.1111\/his.13230","journal-title":"Histopathology"},{"key":"4354_CR63","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1210\/jc.2016-3756","volume":"102","author":"AV Chintakuntlawar","year":"2017","unstructured":"Chintakuntlawar AV, Rumilla KM, Smith CY et al (2017) Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study. J Clin Endocrinol Metab 102:1943\u20131950. https:\/\/doi.org\/10.1210\/jc.2016-3756","journal-title":"J Clin Endocrinol Metab"},{"key":"4354_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0378-y","volume":"6","author":"PC Iyer","year":"2018","unstructured":"Iyer PC, Dadu R, Gule-Monroe M et al (2018) Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer 6:68. https:\/\/doi.org\/10.1186\/s40425-018-0378-y","journal-title":"J Immunother Cancer"},{"key":"4354_CR65","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12020-019-01865-5","volume":"64","author":"S Cantara","year":"2019","unstructured":"Cantara S, Bertelli E, Occhini R et al (2019) Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. Endocrine 64:122\u2013129. https:\/\/doi.org\/10.1007\/s12020-019-01865-5","journal-title":"Endocrine"},{"key":"4354_CR66","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1210\/jc.2018-01167","volume":"104","author":"R Giannini","year":"2019","unstructured":"Giannini R, Moretti S, Ugolini C et al (2019) Immune profiling of thyroid carcinomas suggests the existence of two major phenotypes: an ATC-like and a PDTC-like. J Clin Endocrinol Metab 104:3557\u20133575. https:\/\/doi.org\/10.1210\/jc.2018-01167","journal-title":"J Clin Endocrinol Metab"},{"key":"4354_CR67","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.19.02727","volume":"38","author":"J Capdevila","year":"2020","unstructured":"Capdevila J, Wirth LJ, Ernst T et al (2020) PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol 38:2620\u20132627. https:\/\/doi.org\/10.1200\/JCO.19.02727","journal-title":"J Clin Oncol"},{"key":"4354_CR68","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1089\/thy.2020.0322","volume":"31","author":"C Dierks","year":"2021","unstructured":"Dierks C, Seufert J, Aumann K et al (2021) Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid 31:1076\u20131085. https:\/\/doi.org\/10.1089\/thy.2020.0322","journal-title":"Thyroid"},{"key":"4354_CR69","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12814","volume":"22","author":"S Cameselle-Garc\u00eda","year":"2021","unstructured":"Cameselle-Garc\u00eda S, Abdulkader-Sande S, S\u00e1nchez-Ares M et al (2021) PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: a retrospective study. Oncol Lett 22:553. https:\/\/doi.org\/10.3892\/ol.2021.12814","journal-title":"Oncol Lett"},{"key":"4354_CR70","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/thy.2020.0312","volume":"31","author":"J Ahn","year":"2021","unstructured":"Ahn J, Jin M, Song E et al (2021) Immune profiling of advanced thyroid cancers using fluorescent multiplex immunohistochemistry. Thyroid 31:61\u201367. https:\/\/doi.org\/10.1089\/thy.2020.0312","journal-title":"Thyroid"},{"key":"4354_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.859013","volume":"13","author":"Y Luo","year":"2022","unstructured":"Luo Y, Yang Y-C, Shen C-K et al (2022) Immune checkpoint protein expression defines the prognosis of advanced thyroid carcinoma. Front Endocrinol (Lausanne) 13:859013. https:\/\/doi.org\/10.3389\/fendo.2022.859013","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"4354_CR72","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.47009\/jamp.2023.5.4.233","volume":"5","author":"RK Mohan","year":"2023","unstructured":"Mohan RK, Rajendran AB, Raveendran R (2023) PD-L1 expression in thyroid carcinoma and its association with clinicopathological findings: a hospital-based study from South India. Int J Acad Med Pharm 5(4):1154\u20131159. https:\/\/doi.org\/10.47009\/jamp.2023.5.4.233","journal-title":"Int J Acad Med Pharm"},{"key":"4354_CR73","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4103\/jcrt.jcrt_1471_22","volume":"19","author":"M Boruah","year":"2023","unstructured":"Boruah M, Gaddam P, Agarwal S et al (2023) PD-L1 expression in rare and aggressive thyroid cancers: a preliminary investigation for a role of immunotherapy. J Cancer Res Ther 19:312\u2013320. https:\/\/doi.org\/10.4103\/jcrt.jcrt_1471_22","journal-title":"J Cancer Res Ther"},{"key":"4354_CR74","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/biomedicines12061304","volume":"12","author":"B Chern","year":"2024","unstructured":"Chern B, Pinto D, Lum JH, Parameswaran R (2024) Nearly half of patients with anaplastic thyroid cancer may be amenable to immunotherapy. Biomedicines 12:1304. https:\/\/doi.org\/10.3390\/biomedicines12061304","journal-title":"Biomedicines"},{"key":"4354_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213632","volume":"16","author":"L Shobab","year":"2024","unstructured":"Shobab L, Al-Souri D, Mathews-Kim L et al (2024) PD-L1 expression varies in thyroid cancer types and is associated with decreased progression free survival (PFS) in patients with anaplastic thyroid cancer. Cancers (Basel) 16:3632. https:\/\/doi.org\/10.3390\/cancers16213632","journal-title":"Cancers (Basel)"},{"key":"4354_CR76","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12902-024-01555-y","volume":"24","author":"D Soll","year":"2024","unstructured":"Soll D, Bischoff P, Frisch A et al (2024) First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study. BMC Endocr Disord 24:25. https:\/\/doi.org\/10.1186\/s12902-024-01555-y","journal-title":"BMC Endocr Disord"},{"key":"4354_CR77","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1001\/jamaoncol.2024.4729","volume":"10","author":"ME Cabanillas","year":"2024","unstructured":"Cabanillas ME, Dadu R, Ferrarotto R et al (2024) Anti-programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: a nonrandomized clinical trial. JAMA Oncol 10:1672\u20131680. https:\/\/doi.org\/10.1001\/jamaoncol.2024.4729","journal-title":"JAMA Oncol"},{"key":"4354_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1365055","volume":"14","author":"J Chen","year":"2024","unstructured":"Chen J, Xiao Z, Wu H (2024) Research progress of immunotherapy against anaplastic thyroid cancer. Front Oncol 14:1365055. https:\/\/doi.org\/10.3389\/fonc.2024.1365055","journal-title":"Front Oncol"},{"key":"4354_CR79","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1089\/thy.2022.0073","volume":"32","author":"A Hatashima","year":"2022","unstructured":"Hatashima A, Archambeau B, Armbruster H et al (2022) An evaluation of clinical efficacy of immune checkpoint inhibitors for patients with anaplastic thyroid carcinoma. Thyroid 32:926\u2013936. https:\/\/doi.org\/10.1089\/thy.2022.0073","journal-title":"Thyroid"},{"key":"4354_CR80","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1089\/thy.2019.0086","volume":"29","author":"AV Chintakuntlawar","year":"2019","unstructured":"Chintakuntlawar AV, Yin J, Foote RL et al (2019) A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer. Thyroid 29:1615\u20131622. https:\/\/doi.org\/10.1089\/thy.2019.0086","journal-title":"Thyroid"},{"key":"4354_CR81","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1089\/thy.2022.0050","volume":"32","author":"NY Lee","year":"2022","unstructured":"Lee NY, Riaz N, Wu V et al (2022) A pilot study of Durvalumab (MEDI4736) with Tremelimumab in combination with image-guided stereotactic body radiotherapy in the treatment of metastatic anaplastic thyroid cancer. Thyroid 32:799\u2013806. https:\/\/doi.org\/10.1089\/thy.2022.0050","journal-title":"Thyroid"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04354-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04354-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04354-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:10:16Z","timestamp":1772694616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04354-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4354"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04354-5","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}